Synergy Pharmaceuticals
SGYP
SGYP was delisted on the 7th of March, 2019.
89 hedge funds and large institutions have $4.12M invested in Synergy Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 16 increasing their positions, 39 reducing their positions, and 56 closing their positions.
24.22% less ownership
Funds ownership: 38.82% → 14.61% (-24%)
33% less funds holding
Funds holding: 133 → 89 (-44)
41% less call options, than puts
Call options by funds: $141K | Put options by funds: $239K
59% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 39
77% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 56
95% less capital inflows, than outflows
Capital inflows: $3.26M | Capital outflows: $61M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jefferies Group
New York
|
+$1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$335K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$317K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$173K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$171K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nantahala Capital Management
New Canaan,
Connecticut
|
-$14M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$12.4M |
| 3 |
BlackRock
New York
|
-$6.7M |
| 4 |
State Street
Boston,
Massachusetts
|
-$4.66M |
| 5 |
Hikari Power
Tokyo,
Japan
|
-$4.25M |
SGYP Hedge Fund Activity: Q4 2018 in Review
89 of the 4,507 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals (SGYP) for Q4 2018, worth a combined $4.12M — down 97% from $164M a quarter earlier.
Sellers outnumbered buyers: 56 funds closed out of SGYP and 13 opened new positions — a net loss of 43 holders — while 39 trimmed existing stakes and 16 added.
The largest buyer was Jefferies Group, adding an estimated $1M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $14M sold.
- 89 institutional investors held Synergy Pharmaceuticals (SGYP) as of Q4 2018, down from 133 in Q3 2018.
- Funds reported $4.12M of Synergy Pharmaceuticals stock for Q4 2018, down 97% quarter-over-quarter.
- 13 funds opened new Synergy Pharmaceuticals positions in Q4 2018 and 56 closed out, a net change of -43 holders.
- The largest Synergy Pharmaceuticals buyer in Q4 2018 was Jefferies Group, an estimated $1M added.
- The largest Synergy Pharmaceuticals seller in Q4 2018 was Nantahala Capital Management, an estimated $14M sold.
Based on aggregated 13F filings for Q4 2018.